From AKI dosing to CKM therapeutic inertia, experts at ASN Kidney Week 2026 pointed to pharmacists as key to moving new kidney data into practice.
News|Articles|March 13, 2026
Data Show Significantly Higher Gabapentin Use in SUD Treatment Settings
Fact checked by: Ron Panarotti
Although the rates of gabapentin use without a prescription were nearly double those of prescribed use, the trends are decreasing over time.
Advertisement
Advertisement
Gabapentin prescribing has increased in substance use disorder (SUD) treatment settings despite a lack of strong evidence for its utility, according to authors of research published in Drug and Alcohol Dependence. Although rates of gabapentin use outside a prescription were nearly double those for prescribed use, this appears to be decreasing over time.1
Related to this article
Pharmacists can support effective cancer pain treatment by starting constipation prevention with opioid therapy and reassessing bowel function before symptoms become a barrier to care.
Jai Radhakrishnan, MD, MBBS, MS, FASN, discusses why IgG4-related kidney disease is often missed and what the MITIGATE subgroup data presented at ASN Kidney Week 2026 show.
Pharmacy Times featured experts on kidney function assessment, IgG4-related disease, emerging CKD therapies, and gaps in cardiorenal care.
October’s oncology coverage highlighted new treatment options in rectal, breast, and prostate cancers, alongside longer-term survival findings and concerns about reduced-frequency immunotherapy.
Young adults who vaped daily but never smoked had lower flow-mediated dilation and peak oxygen uptake than peers who used neither product.
ESMO 2026 lung cancer trials reshape care: tarlatamab maintenance, divarasib leads KRAS G12C, MET resistance combos and TROP2 ADCs expand pharmacist monitoring.
ESMO 2026 breast cancer updates show ribociclib boosts survival, while immunotherapy and extended endocrine therapy improve end points without longer overall survival.
Advertisement
Advertisement